Title of article
Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention
Author/Authors
Cheneau، نويسنده , , Edouard and Canos، نويسنده , , Daniel and Kuchulakanti، نويسنده , , Pramod K. and Rha، نويسنده , , Seung-Woon and Satler، نويسنده , , Lowell F. and Suddath، نويسنده , , William O. and Kent، نويسنده , , Kenneth M. and Pichard، نويسنده , , Augusto D. and Waksman، نويسنده , , Ron، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
4
From page
789
To page
792
Abstract
Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.
Journal title
American Journal of Cardiology
Serial Year
2004
Journal title
American Journal of Cardiology
Record number
1898112
Link To Document